Cosmetic Science (FB 13), University of Hamburg, Germany.
J Dtsch Dermatol Ges. 2012 Feb;10(2):115-9. doi: 10.1111/j.1610-0387.2011.07750.x. Epub 2011 Aug 16.
Primary focal hyperhidrosis plantaris can cause impairment in social, physical, leisure and occupational activities. Topical treatment with aluminium chloride is the first-line treatment. The aim of this trial was to evaluate efficacy and safety of two different concentrations of aluminium chloride hexa-hydrate (12.5%, 30%) for 6 weeks.
20 volunteers with hyperhidrosis plantaris were included. Efficacy was evaluated using a clinical rating scale of the hyperhidrosis level and qualitative assessments including Minor's (iodine-starch) test and a standardized sniff test. Furthermore a patient questionnaire and measurements of skin surface pH were done to evaluate the subjective assessments and side effects.
The hyperhidrosis level significantly decreased in both concentrations. There were no differences in tolerability regarding the skin surface pH and the patient questionnaires. In addition the hidrotic areas decreased after application of both products and the sniff test improved.
Topical application of an antiperspirant containing aluminium chloride reduced sweat production in plantar hyperhidrosis significantly. As both 12.5% and 30% were efficacious and safe, we would recommend 12.5% for outpatient treatment.
原发性局限性多汗症可导致社会、身体、休闲和职业活动受损。氯化铝局部治疗是一线治疗。本试验旨在评估六星期内使用两种不同浓度的六水合氯化铝（12.5%，30%）的疗效和安全性。
共纳入 20 名足底多汗症志愿者。采用多汗症严重程度临床评分、Minor（碘淀粉）试验和标准化嗅探试验进行疗效评估。此外，还进行了患者问卷调查和皮肤表面 pH 值测量，以评估主观评估和副作用。
两种浓度均显著降低了多汗症的严重程度。皮肤表面 pH 值和患者问卷调查方面的耐受性无差异。此外，两种产品应用后多汗区域减少，嗅探试验改善。
局部应用含氯化铝的止汗剂可显著减少足底多汗症的汗液分泌。由于 12.5%和 30%均有效且安全，我们建议门诊治疗使用 12.5%。
